SWM
PTCT icon

Spire Wealth Management’s PTC Therapeutics PTCT Stock Holding History

Spire Wealth Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$979 Hold
12
– – ﹤0.01% 2140
2026
Q1 		$818 Sell
12
-1
-8% -$71 ﹤0.01% 2175
2025
Q4 		$987 Buy
+13
New +$945 ﹤0.01% 2196
2023
Q2 		– Sell
-142
Closed -$6.88K – 2504
2023
Q1 		$6.88K Buy
142
+39
+38% +$1.78K ﹤0.01% 1964
2022
Q4 		$4K Buy
+103
New +$4.28K ﹤0.01% 1912

Other funds holding PTCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Spire Wealth Management's PTCT Position: Q2 2026 in Review

Spire Wealth Management held its PTC Therapeutics (PTCT) position steady in Q2 2026 at 12 shares worth $979. The position accounts for ﹤0.01% of the portfolio, ranked #2140.

Spire Wealth Management first reported a position in PTCT in Q4 2022 and has held it in 5 quarters since. The position peaked at $6.88K in Q1 2023. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

  • Spire Wealth Management held 12 shares of PTC Therapeutics worth $979 as of Q2 2026.
  • Spire Wealth Management left its PTC Therapeutics share count unchanged in Q2 2026.
  • PTC Therapeutics made up ﹤0.01% of Spire Wealth Management's portfolio in Q2 2026, its #2140 holding.
  • Spire Wealth Management first reported a position in PTC Therapeutics in Q4 2022 and has held it in 5 quarters since.
  • Spire Wealth Management's PTC Therapeutics position peaked at $6.88K in Q1 2023.
  • 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Spire Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.